Early effects of rhenium-188 treatment on proliferation, migration, and matrix synthesis of cultured human aortic smooth muscle cells

Strahlentherapie und Onkologie

Volumn 182, Issue 3, 2006, Pages 164-171

  Kehlbach, Rainer ^a   Dittmann, Helmut ^a   Schmid, Thilo ^b   Khorchidi, Sascha ^a   Bantleon, Rüdiger ^a   Rodemann, H Peter ^a   Claussen, Claus D ^a   Duda, Stephan H ^a,c   Wiskirchen, Jakub ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Boeblingen Hospital   (Germany)

^c Jewish Hospital Berlin   (Germany)

Author keywords

Angioplasty; Intravascular irradiation; Radioactive stents; Radionuclide; Restenosis

Indexed keywords

RADIOISOTOPE; RHENIUM 188; SCLEROPROTEIN; TENASCIN; RHENIUM;

AORTA; ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; EVALUATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; IN-STENT RESTENOSIS; MITOSIS INHIBITION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEIN SYNTHESIS; RADIATION DOSE FRACTIONATION; SMOOTH MUSCLE FIBER; STENT; CELL CULTURE; CELL DIVISION; CELL LINE; CELL MOTION; CYTOLOGY; PHYSIOLOGY; RADIATION EXPOSURE; RADIATION RESPONSE; VASCULAR SMOOTH MUSCLE;

AORTA; CELL DIVISION; CELL LINE; CELL MOVEMENT; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MUSCLE, SMOOTH, VASCULAR; RADIOISOTOPES; RHENIUM;

EID: 33646088154     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-006-1459-2     Document Type: Article

References (48)

1. Albiero R, Nishida T, Adamian M, et al. Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. Circulation 2000;101:2454-7.
2. Bartek J, Lukas C, Lukas J. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 2004;5:792-804.
3. Bornfeldt KE, Raines ET, Nakano T, et al. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994;93:1266-74.
4. Carter AJ, Aggarwal M, Kopia GA, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 2004;63:617-24.
5. Cordes N, Beinke C, Plasswilm L, et al. Irradiation and various cytotoxic drugs enhance tyrosine phosphorylation and beta(1)-integrin clustering in human A549 lung cancer cells in a substratum-dependent manner in vitro. Strahlenther Onkol 2004;180:157-64.
6. Cordes N, van Beuningen D. Arrest of human lung fibroblasts in G2 phase after irradiation is regulated by converging phosphatidylinositol-3 kinase and beta1-integrin signaling in vitro. Int J Radiat Oncol Biol Phys 2004;58:453-62.
7. Dittmann K. Toulany M, Classen J, et al. Selective radioprotection of normal tissues by Bowman-Birk proteinase inhibitor (BBI) in mice. Strahlenther Onkol 2005;181:191-6.
8. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005;16:331-8.
9. Duda SH, Poerner TC, Wiesinger B, et al. Drug-eluting stents: potential applications for peripheral arterial occlusive disease. J Vasc Interv Radiol 2003;14:291-301.
10. Erickson HP, Bourdon MA. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol 1989;5:71-92.
11. Fareh J, Martel R, Kermani P, et al. Cellular effects of beta-particle delivery on vascular smooth muscle cells and endothelial cells: a dose-response study. Circulation 1999;99:1477-84.
12. Fischer-Dzoga K, Dimitrievich GS, Schaffner T. Effect of hyperlipidemic serum and irradiation on wound healing in primary quiescent cultures of vascular cells. Exp Mol Pathol 1990;52:1-12.
13. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
14. Fukui R, Amakawa M, Hoshiga M, et al. Increased migration in late G(1) phase in cultured smooth muscle cells. Am J Physiol Cell Physiol 2000;279:C999-1007.
15. Gallino A, Do DD, Alerci M, et al. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. J Endovasc Ther 2004;11:595-604.
16. Geffrotin C, Tricaud Y, Crechet F, et al. Unlike tenascin-X, tenascin-C is highly up-regulated in pig cutaneous and underlying muscle tissue developing fibrosis after necrosis induced by very high-dose gamma radiation. Radiat Res 1998;149:472-81.
17. Hafeli UO, Warburton MC, Landau U. Electrodeposition of radioactive rhenium onto stents to prevent restenosis. Biomaterials 1998;19:925-33.
18. Heckenkamp J, Nigri GR, Waterman PR, et al. Gamma-irradiation modulates vascular smooth muscle cell and extracellular matrix function: implications for neointimal development. J Vasc Surg 2004;39:1097-103.
19. Hehrlein C, Gollan C, Donges K, et al. Low-dose radioactive endovascular stents prevent smooth muscle cell proliferation and neointimal hyperplasia in rabbits. Circulation 1995;92:1570-5.
20. 188Rhenium on the growth of human vessel wall cells.] Rofo Fortsch Geb Röntgenstr Neuen Bildgeb Verfahr 2004;176:404-8.
21. Ilmonen S, Jahkola T, Turunen JP, et al. Tenascin-C in primary malignant melanoma of the skin. Histopathology 2004;45:405-11.
22. Imanaka-Yoshida K, Matsuura R, Isaka N, et al. Serial extracellular matrix changes in neointimal lesions of human coronary artery after percutaneous transluminal coronary angioplasty: clinical significance of early tenascin-C expression. Virchows Arch 2001;439:185-90.
23. Kawrakow I, Fippel M, Friedrich K. 3D electron dose calculation using a voxel based Monte Carlo algorithm (VMC). Med Phys 1996;23:445-57.
24. Kim HS, Cho HJ, Cho HJ, et al. The essential role of p21 in radiation-induced cell cycle arrest of vascular smooth muscle cell. J Mol Cell Cardiol 2004;37:871-80.
25. Klemke RL, Cai S, Giannini AL, et al. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997;137:481-92.
26. Konemann S, Hesselmann S, Bolling T, et al. Radiotherapy of benign diseases. Scleredema adultorum Buschke. Strahlenther Onkol 2004;180:811-4.
27. Kotzerke J, Hanke H, Hoher M. Endovascular brachytherapy for the prevention of restenosis after angioplasty. Eur J Nucl Med 2000;27:223-36.
28. Koukoulis GK, Gould VE, Bhattacharyya A, et al. Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Hum Pathol 1991;22:636-43.
29. Krueger K, Zaehringer M, Bendel M, et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty - angiographic and clinical follow-up in a prospective randomized controlled trial. Radiology 2004;231:546-54.
30. Lev EI, Assali AR, Teplisky I, et al. Comparison of outcomes up to six months of heparin-coated with noncoated stents after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2004;93:741-3.
31. Nag S, Cole PE, Crocker I, et al. The American Brachytherapy Society perspective on intravascular brachytherapy. Cardiovasc Radiat Med 1999;1:8-19.
32. Nelson PR, Yamamura S, Mureebe L, et al. Smooth muscle cell migration and proliferation are mediated by distinct phases of activation of the intracellular messenger mitogen-activated protein kinase. J Vasc Surg 1998;27:117-25.
33. Raizner AE, Kaluza GL, The Proliferation REduction with Vascular ENergy Trial (PREVENT). Curr Control Trials Cardiovasc Med 2001;2:16-9.
34. Riekki R, Jukkola A, Oikarinen A, et al. Radiation therapy induces tenascin expression and angiogenesis in human skin. Acta Derm Venereol 2001;81:329-33.
35. Seegenschmiedt MH, Micke O, Willich N. Radiation therapy for nonmalignant diseases in Germany. Current concepts and future perspectives. Strahlenther Onkol 2004;180:718-30.
36. Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart 2002;87:305-7.
37. Sindermann JR, Verin V, Hopewell JW, et al. Biological aspects of radiation and drug-eluting stents for the prevention of restenosis. Cardiovasc Res 2004;63:22-30.
38. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538-46.
39. Steel GG. Clonogenic cells and the concept of cell survival. In: Steel GG, ed. Basic clinical radiobiology. London: Arnold, 1993:28-39.
40. Stone GW, Ellis SG, Cox DA, et al., TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-7.
41. Swindle CS, Tran KT, Johnson TD, et al. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol 2001;154:459-68.
42. Tanner FC, Yang ZY, Duckers E, et al. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res 1998;82:396-403.
43. Teirstein PS, King S. Vascular radiation in a drug-eluting stent world: it's not over till it's over. Circulation 2003;108:384-5.
44. Verin V, Popowski Y, de Bruyne B, et al. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study Group. N Engl J Med 2001;344:243-9.
45. Waksman R, Raizner A, Popma JJ. Beta emitter systems and results from clinical trials. state of the art. Cardiovasc Radiat Med 2003;4:54-63.
46. Wallner K, Li C, Shah PK, et al. Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation 1999;99:1284-9.
47. Wiskirchen J, Dittmann H, Kehlbach R, et al. Rhenium-188 for inhibition of human aortic smooth muscle cell proliferation. Int J Radiat Oncol Biol Phys 2001;49:809-15.
48. Wolfram RM, Budinsky AC, Pokrajac B, et al. Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery - the Vienna experience. Radiology 2005;236:343-51.